Kyverna Therapeutics, Inc.
KYTX
$1.87
-$0.04-2.09%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 33.48M | 29.19M | 27.32M | 22.48M | 17.16M |
| Gross Profit | -33.48M | -29.19M | -27.32M | -22.48M | -17.16M |
| SG&A Expenses | 10.36M | 7.88M | 6.11M | 5.78M | 4.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.84M | 37.07M | 33.44M | 28.26M | 21.38M |
| Operating Income | -43.84M | -37.07M | -33.44M | -28.26M | -21.38M |
| Income Before Tax | -37.49M | -34.49M | -28.80M | -26.69M | -20.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.49M | -34.49M | -28.80M | -26.69M | -20.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.49M | -34.49M | -28.80M | -26.69M | -20.67M |
| EBIT | -43.84M | -37.07M | -33.44M | -28.26M | -21.38M |
| EBITDA | -43.52M | -36.75M | -33.14M | -28.01M | -21.15M |
| EPS Basic | -0.87 | -0.80 | -0.67 | -1.12 | -25.94 |
| Normalized Basic EPS | -0.58 | -0.47 | -0.42 | -0.67 | -16.21 |
| EPS Diluted | -0.87 | -0.80 | -0.67 | -1.12 | -25.94 |
| Normalized Diluted EPS | -0.58 | -0.47 | -0.42 | -0.67 | -16.21 |
| Average Basic Shares Outstanding | 43.23M | 43.16M | 43.13M | 23.75M | 796.60K |
| Average Diluted Shares Outstanding | 43.23M | 43.16M | 43.13M | 23.75M | 796.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
